{"disease":{"id":"fgfr2-gene-mutation","name":"fgfr2 gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04526106","title":"REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"Elevar Therapeutics","has_results":false},{"nct_id":"NCT02150967","title":"A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":143,"lead_sponsor_name":"QED Therapeutics, a BridgeBio company","has_results":true},{"nct_id":"NCT04919642","title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"TransThera Sciences (Nanjing), Inc.","has_results":false},{"nct_id":"NCT03773302","title":"Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":48,"lead_sponsor_name":"QED Therapeutics, a BridgeBio company","has_results":true},{"nct_id":"NCT04096417","title":"Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":14,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT05052372","title":"Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib","phase":"","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT05565794","title":"Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT02706691","title":"BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"University of Chicago","has_results":true}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}